Fi Recalls Two Dog Supplements Over Potential Salmonella Contamination

Fi, the U.S. pet-health brand owned by Vet Plus, Inc., has recalled two dog dietary supplements because they may be contaminated with Salmonella.

The U.S. Food and Drug Administration (FDA) published the company recall notice on September 8, 2026, following a company announcement dated September 3. The affected products were sold directly to consumers and through major online channels including Amazon and Chewy.com.

The recall covers:

The FDA states that the potential contamination originated from an ingredient supplied to Fi’s manufacturer. The manufacturer has suspended production while it investigates the issue.

What Happened?

According to the FDA’s official recall notice, Fi initiated the recall after being notified that an ingredient supplied to its manufacturing partner could potentially be contaminated with Salmonella. The company is therefore dealing with a raw-material / ingredient-level contamination risk, rather than an allegation that every Fi supplement product is contaminated.

This distinction is important. The recall applies specifically to the two identified products and lots:

• Fi Calming Supplement for Dogs — Lot 26118

• Fi 8-in-1 Formula Supplement for Dogs — Lot 26159

The FDA’s recall database lists the action under Animal & Veterinary → Supplements → Potential contamination with Salmonella.

Why Salmonella Is a Significant Pet-Health Risk

Salmonella represents a dual-risk issue in companion-animal products because contaminated supplements can potentially affect both the animal consuming the product and people handling the product or exposed to contaminated animal waste.

In dogs, possible signs include:

• lethargy

• decreased appetite

• abdominal pain

• fever

• diarrhea

• bloody diarrhea

• vomiting

Importantly, the FDA notes that some otherwise healthy animals may carry Salmonella without obvious clinical signs and potentially transmit the organism to other animals or humans. For humans, possible symptoms include nausea, vomiting, diarrhea or bloody diarrhea, abdominal cramps and fever.

Supply-Chain Risk Is the Bigger Industry Signal

For the animal-health industry, the most important aspect of this recall may be where the contamination risk originated.

The FDA notice specifically identifies an ingredient supplied to the manufacturer as the potential source. This illustrates a growing vulnerability in the rapidly expanding pet-supplement market: brands can have limited direct control over upstream ingredient production, testing, storage and handling. The incident therefore reinforces the importance of:

1. Supplier qualification

2. Raw-material microbiological testing

3. Lot traceability

4. Environmental monitoring

5. Manufacturing hygiene

6. Finished-product testing

7. Rapid recall capability

8. Digital consumer traceability

This becomes particularly important as pet supplements move from a niche category into mainstream preventive pet health.

E-Commerce Increases Recall Complexity

The affected products were sold through Amazon, Chewy.com and directly to consumers. That distribution model has two contrasting effects.

Advantage: Digital sales provide potentially strong transaction-level traceability.

Risk: Products can be distributed rapidly across a geographically dispersed consumer base, making physical recall execution more complex.

For pet-health companies operating DTC or through marketplaces, the ability to identify affected customers by SKU + lot number + purchase date is increasingly becoming a core quality-management capability.

Industry Context

FDA’s animal-health recall database shows that Salmonella and other microbiological or formulation-related quality events remain a recurring issue across the U.S. pet-food and pet-supplement industry.

The FDA database currently lists, among other recent actions, recalls involving Northwest Naturals, Oma’s Pride and other pet products.

The Fi case is therefore not an isolated regulatory phenomenon; rather, it sits within a broader environment in which pet nutrition, supplements and functional-health products are increasingly being treated as products requiring rigorous quality and traceability controls.

Strategic / Investor View

From an investor and animal-health-industry perspective, this is a manageable but strategically relevant quality event. The immediate financial impact is likely to be concentrated around:

• recalled inventory;

• replacement/refund costs;

• manufacturing interruption;

• testing and investigation;

• logistics;

• customer communication;

• potential reputational impact.

The larger strategic issue is the growing convergence between pet wellness and regulated product-quality expectations.

Fi’s broader ecosystem already spans GPS tracking, health monitoring and pet wellness. Its official support platform describes Fi supplements as part of its science-backed nutrition offering. This means product-quality events in the supplement business can potentially affect trust in a broader pet-health platform.

What Pet-Health Companies Should Learn

The episode highlights five important priorities for the companion-animal sector:

1. Ingredient qualification is becoming strategic.
Supplier auditing cannot be treated merely as a procurement function.

2. Microbiological risk needs end-to-end control.
Testing only finished products may not be sufficient where contamination can enter through ingredients.

3. Lot-level traceability is essential.
Digital pet-health companies have an opportunity to build highly granular recall systems.

4. Preventive-health positioning increases the importance of trust.
Consumers buying supplements are effectively purchasing a health proposition, not simply a commodity.

5. E-commerce creates both risk and opportunity.
Amazon/Chewy/DTC distribution increases market reach while simultaneously creating better digital traceability.

Bottom Line

The Fi recall is relatively narrow in product scope — two products and two identified lots — but it provides a useful industry-level warning.

As the U.S. pet-care market shifts toward supplements, functional nutrition and preventive health, quality assurance, supplier control and microbiological testing are becoming competitive capabilities rather than back-office compliance functions.

For animal-health investors and strategic buyers, the case reinforces the importance of conducting deeper due diligence on contract manufacturers, ingredient suppliers, quality systems, recall history and lot-level traceability when evaluating pet-wellness businesses.